At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Inhaled beclomethasone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients
In Brief
A Phase 2 clinical trial evaluating Inhaled beclomethasone and Placebo for Lung Transplant Infection. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if the use of inhaled beclomethasone after a community-acquired respiratory viral infection in a lung transplant recipient decreases the risk of the subsequent development of chronic lung allograft dysfunction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Transplant Infection
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartFeb 2017
Primary CompletionJan 2021
TodayJul 2026
First PostedJan 30, 2015
Enrollment StartFeb 1, 2017
Primary CompletionJan 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 11.4 years ago
Interventions
Inhaled beclomethasonedrug
Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
Placebodrug
Placebo will serve as a control treatment